Category Archives: Cell Therapy

PURTIER Placenta Live Stem Cell Therapy CHINESE By: Joanne Chin … Continue reading →

(PRWEB) May 02, 2014 The report Stem Cell Therapy Market by Treatment Mode (Autologous & Allogeneic), Therapeutic Applications (CNS, CVS, GIT, Wound Healing, Musculoskeletal, Eye, & Immune System) - Regulatory Landscape, Pipeline Analysis & Global Forecasts to 2020 analyzes and studies the major market drivers, restraints, opportunities, and challenges in North America, Asia-Pacific, Europe, and the Rest of the World (RoW). Browse 57 market data tables 32 figures spread through 196 Slides and in-depth TOC on Stem Cell Therapy Market http://www.marketsandmarkets.com/Market-Reports/stem-cell-technologies-and-global-market-48.html Early buyers will receive 10% customization on report. This report studies the global stem cell therapy market over the forecast period of 2015 to 2020.The market is poised to grow at a CAGR of 39.5% from 2015 to 2020, to reach $330million by 2020. Download Free PDF Download @ http://www.marketsandmarkets.com/pdfdownload.asp?id=48 The global stem cell therapy market on the basis of the mode of treatment is segmented into allogeneic and autologous stem cell therapy. In addition, based on the therapeutic applications, the global stem cell therapy market is segmented into eye diseases, metabolic diseases, GIT diseases, musculoskeletal disorders, immune system diseases, CNS diseases, CVS diseases, wounds and injuries, and others. Inquire Before Buying @ http://www.marketsandmarkets.com/Enquiry_Before_Buying.asp?id=48 A number of factors such … Continue reading →

Heart cells created from human embryonic stem cells successfully restored damaged heart muscles in monkeys. The results of the experiment appear in the April 30 advanced online edition of the journal Nature in a paper titled, "Human embryonic-stem cell derived cardiomyocytes regenerate non-human primate hearts." The findings suggest that the approach should be feasible in humans, the researchers said. "Before this study, it was not known if it is possible to produce sufficient numbers of these cells and successfully use them to remuscularize damaged hearts in a large animal whose heart size and physiology is similar to that of the human heart," said Dr. Charles Murry, UW professor of pathology and bioengineering, who led the research team that conducted the experiment. A physician/scientist, Murry directs the UW Center for Cardiovascular Biology and is a UW Medicine pathologist. Murry said he expected the approach could be ready for clinical trials in humans within four years. In the study, Murry, along with Dr. Michael Laflamme and other colleagues at the UW Institute for Stem Cell & Regenerative Medicine, experimentally induced controlled myocardial infarctions, a form of heart attack, in anesthetized pigtail macaques. The infarcts were created by blocking the coronary artery of … Continue reading →

Stem cell therapy | irish stem cells http://www.arthritistreatmentcenter.com So what's going on in Ireland when it comes to arthritis... coming up next... First signs of arthritis cure seen by Irish researchers The first signs... By: Nathan Wei … Continue reading →

New York, NY (PRWEB) April 29, 2014 The Stem Cell Institute located in Panama City, Panama, welcomes special guest speaker Roberta F. Shapiro, DO, FAAPM&R to its public seminar on umbilical cord stem cell therapy on Saturday, May 17, 2014 in New York City at the New York Hilton Midtown from 1:00 pm to 4:00 pm. Dr. Shapiro will discuss A New York Doctors Path to Panama. Dr. Shapiro operates a private practice for physical medicine and rehabilitation in New York City. Her primary professional activities include outpatient practice focused on comprehensive treatment of acute and chronic musculoskeletal and myofascial pain syndromes using manipulation techniques, trigger point injections, tendon injections, bursae injections, nerve and motor point blocks. Secondary work at her practice focuses on the management of pediatric onset disability. She is the founder and president of the Dayniah Fund, a non-profit charitable foundation formed to support persons with progressive debilitating diseases who are faced with catastrophic events such as surgery or illness. The Dayniah Fund educates the public about the challenges of people with disabilities and supports research on reducing the pain and suffering caused by disabling diseases and conditions. Dr. Shapiro serves as assistant clinical professor in the … Continue reading →

Stem cell therapy | safety of stem cells http://www.arthritistreatmentcenter.com So... are stem cells really safe? The answer next... Safety Of Autologous Adipose Tissue-derived Stem Cells With Platelet-rich plasma Into Human Articular... By: Nathan Wei … Continue reading →

By Estel Grace Masangkay Aastrom Biosciences announced that it has signed a definitive agreement to acquire Sanofis Cell Therapy and Regenerative Medicine (CTRM) business for $6.5 million. Sanofi will receive $4 million in cash at closing and $2.5 million in promissory. The transaction is subject to customary closing conditions and is expected to be completed in about three weeks. Nick Colangelo, president and CEO of Aastrom, said, The acquisition of Sanofi's CTRM business is a transformative transaction that positions Aastrom as a fully-integrated global regenerative medicine company. The CTRM business brings us global manufacturing, marketing and sales capabilities that are structured to support the current portfolio of marketed products as well as our future product development plans. This transaction also provides us with a platform to generate operating income to support the development of our high-potential pipeline products and continued growth through additional strategic transactions. Through its acquisition of CTRM, Aastrom acquires global rights to three marketed autologous cell therapy products. These are Carticel (autologous cultured chondrocytes), Epicel (cultured epidermal autografts), and MACI (matrix-induced autologous chondrocyte implant). Carticel is approved and marketed in the U.S. for the treatment of articular cartilage defects. Epicel is a permanent skin replacement for burns … Continue reading →

Madison's Before After Stem Cell Therapy Had step cell therapy procedure on 4/14/14 and we were seeing noticeable results only 4 short days later. By: Jaie Locke … Continue reading →

Suggestions For Stem Cell Therapy PRP Treatment For Hair Loss - Good Health Subscribe to Tv5 News Channel: http://goo.gl/NHJD9 Like us on Facebook: http://www.facebook.com/tv5newschannel Follow us on Twitter: https://twitter.co... By: TV5 News … Continue reading →

NEW YORK (TheStreet) --Aastrom Biosciences (ASTM) soared Monday after the company announced its acquisition ofSanofi'sCell Therapy and Regenerative Medicine, or CTRM, business for $6.5 million. Aastrom will pay $4 million in cash and $2.5 million in a promissory note for the business. The company expects the acquisition to close in approximately three weeks. The acquisition gives Aastromglobal commercial rights to three marketed autologous cell therapy products called Carticel, Epicel and MACI.Revenues of those three products totaled $44 million in 2013. Aastrom will also acquiremanufacturing and production centers in the U.S. and Denmark. The stock was up 32.1% to $46.5 at 11:15 a.m., by which point it had eclipsed its average volume of380,200 with more than 1.6 million shares traded for the day. Aastrom hit a high of $4.95 for the day as of that time. "The acquisition of Sanofi's CTRM business is a transformative transaction that positions Aastrom as a fully-integrated global regenerative medicine company," said Aastrom President and CEO Nick Colangelo in a statement. "The CTRM business brings us global manufacturing, marketing and sales capabilities that are structured to support the current portfolio of marketed products as well as our future product development plans. This transaction also provides us … Continue reading →